RECRUITING

Disentangling the Role of Depression in Hypersomnia

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Individuals who have disorders of hypersomnolence (excessive sleepiness) often report symptoms of depression. The goal of this study is to further understand of the relationship between depression and hypersomnia by examining mood-relevant domains of slow wave sleep and reward function.

Official Title

Disentangling the Role of Depression in Hypersomnia

Quick Facts

Study Start:2023-08-01
Study Completion:2025-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05850676

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years to 55 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Males and females between the age of 21 and 55
  2. * Meet DSM5 criteria for Idiopathic Hypersomnia or Hypersomnia Associated with a Psychiatry Disorder
  3. * Ability to read and speak English
  1. * Unable or unwilling to provide informed consent
  2. * Untreated obstructive sleep apnea (apnea-hypopnea index /= 15 events/hr)
  3. * Meeting diagnostic criteria for narcolepsy
  4. * A clinically unstable medical condition as defined by a new diagnosis or change in medical management in the previous 2 months (e.g., pneumonia, thyroid disease, ventricular arrhythmias, cirrhosis, surgery, or recently diagnosed cancer) because these changes could impact daytime hypersomnia and confound results
  5. * Substance abuse/dependence, delirium, dementia, amnestic disorder, schizophrenia, and other psychotic disorders
  6. * Prominent current suicidal or homicidal ideation.
  7. * Unable to perform tests due to inability to communicate verbally, inability to read and write; less than a 5th grade reading level; visal, hearing, or cognitive impairment (e.g. previous head injury)
  8. * Use of medications or OTC products that might impact sleep

Contacts and Locations

Study Contact

Nayeli Nunez-Cruz
CONTACT
215-746-3067
Nayeli.NunezCruz@Pennmedicine.upenn.edu

Principal Investigator

Philip Gehrman, PhD
PRINCIPAL_INVESTIGATOR
University of Pennsylvania

Study Locations (Sites)

The University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States

Collaborators and Investigators

Sponsor: University of Pennsylvania

  • Philip Gehrman, PhD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-08-01
Study Completion Date2025-06-30

Study Record Updates

Study Start Date2023-08-01
Study Completion Date2025-06-30

Terms related to this study

Additional Relevant MeSH Terms

  • Hypersomnia